BIIB News and Press, Biogen Inc. From 01/08/24

2024-01-08 16:48:08 ET Biogen Inc. (BIIB) J.P. Morgan 42nd Annual Healthcare Conference January 08, 2024 02:15 PM EST Company Participants Chris Viehbacher - CEO Conference Call Participants Chris Schott - J.P. Morgan Presentation Chris Schott ...

2024-01-05 09:07:57 ET More on Big Pharma Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bri...

2024-01-05 10:17:57 ET More on Big Pharma Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Bri...

2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...

2024-01-04 11:08:37 ET More on Ginkgo Bioworks Holdings Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty Ginkgo Bioworks: A Long Way To Go Ginkgo Bioworks: More Revenue Issues Gingko Bioworks, Synplogen to advance gene therapy services in Japan ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-28 15:06:23 ET More on AbbVie, Amgen, etc. The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Bristol Myers Squibb: Too Many Headwinds To Ignore, Despit...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-27 11:59:35 ET More on iShares MSCI World Index ETF: U.S. equities continue to lead the world in inflows, China sees large outflows Stocks over bonds as the year ends Dividend scorecard for iShares MSCI World Index ETF For further details see: 24 ...

CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neur...